Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc. (OTC BB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation. The objectives of the Phase IIa clinical trial with SP-304 are to characterize the safety of SP-304 for 14 days in patients with CC and establish doses for the larger planned Phase IIb trial in CC patients.

“SP-304 offers hope to the millions of patients suffering from CC and other human gastrointestinal conditions, for which there are currently limited treatment options”

“SP-304 offers hope to the millions of patients suffering from CC and other human gastrointestinal conditions, for which there are currently limited treatment options,” said Gary S. Jacob, Ph.D., President and CEO of Synergy. “The initiation of this trial is another major milestone in our development of this drug that we believe has the potential of delivering higher efficacy and a better safety profile than any other competitive product.”